Alan Balch, PhD, discusses the Institute for Clinical and Economic Review’s (ICER’s) Value Assessment Framework tool that aims to provide stakeholders in healthcare with evidence to make more informed decisions regarding new cancer therapies. Dr Balch also considers limitations to the tool’s effectiveness.
Plus, he even discusses why if we lived life using a strict cost-benefit approach, perhaps no one would have kids because the benefits of having kids–like the benefits from health care–are so difficult to monetize.